NATEGLINIDE

Nateglinide Adverse Events Reported to the FDA Over Time

How are Nateglinide adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Nateglinide, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Nateglinide is flagged as the suspect drug causing the adverse event.

Most Common Nateglinide Adverse Events Reported to the FDA

What are the most common Nateglinide adverse events reported to the FDA?

Gastritis	45 (2.09%)
Disease Progression	38 (1.76%)
Abdominal Pain	36 (1.67%)
Chest Pain	36 (1.67%)
Gastritis Erosive	32 (1.48%)
Abdominal Pain Upper	29 (1.35%)
Hypertension	29 (1.35%)
Hypoglycaemia	29 (1.35%)
Diarrhoea	28 (1.3%)
Vomiting	27 (1.25%)
Anaemia	26 (1.21%)
	Show More
Asthenia	26 (1.21%)
Colonic Polyp	26 (1.21%)
Small Intestinal Haemorrhage	26 (1.21%)
Dizziness	25 (1.16%)
Dyspnoea	25 (1.16%)
Decreased Appetite	24 (1.11%)
Arteriovenous Malformation	22 (1.02%)
Concomitant Disease Progression	22 (1.02%)
Diverticulum Intestinal	22 (1.02%)
Epistaxis	22 (1.02%)
Faeces Discoloured	22 (1.02%)
Gastrointestinal Haemorrhage	22 (1.02%)
Angiodysplasia	21 (.97%)
Angina Pectoris	17 (.79%)
Pancreatitis	17 (.79%)
Convulsion	14 (.65%)
Hepatic Function Abnormal	14 (.65%)
Liver Disorder	14 (.65%)
Pyrexia	14 (.65%)
Blood Glucose Increased	13 (.6%)
Erythema	13 (.6%)
Musculoskeletal Stiffness	13 (.6%)
Pancreatitis Acute	13 (.6%)
Duodenitis	12 (.56%)
Gastric Ulcer	12 (.56%)
Interstitial Lung Disease	12 (.56%)
Renal Impairment	12 (.56%)
Glycosylated Haemoglobin Increased	11 (.51%)
Haemostasis	11 (.51%)
Lethargy	11 (.51%)
Loss Of Consciousness	11 (.51%)
Reflux Oesophagitis	11 (.51%)
Drug Eruption	10 (.46%)
Hypotension	10 (.46%)
Intestinal Operation	10 (.46%)
Jaundice	10 (.46%)
Laparotomy	10 (.46%)
C-reactive Protein Increased	9 (.42%)
Fatigue	9 (.42%)
Gastric Cancer	9 (.42%)
Gastrooesophageal Reflux Disease	9 (.42%)
Malaise	9 (.42%)
Nausea	9 (.42%)
Osteomyelitis	9 (.42%)
Thrombocytopenia	9 (.42%)
White Blood Cell Count Decreased	9 (.42%)
Blood Alkaline Phosphatase Increase...	8 (.37%)
Fall	8 (.37%)
Gamma-glutamyltransferase Increased	8 (.37%)
Hepatic Steatosis	8 (.37%)
Metastases To Lung	8 (.37%)
Nasopharyngitis	8 (.37%)
Palpitations	8 (.37%)
Platelet Count Decreased	8 (.37%)
Pruritus	8 (.37%)
Renal Disorder	8 (.37%)
Small Intestine Carcinoma	8 (.37%)
Blood Lactate Dehydrogenase Increas...	7 (.32%)
Coronary Artery Disease	7 (.32%)
Hepatitis	7 (.32%)
Melaena	7 (.32%)
Urinary Retention	7 (.32%)
Altered State Of Consciousness	6 (.28%)
Atrial Flutter	6 (.28%)
Blood Urea Increased	6 (.28%)
Bronchitis	6 (.28%)
Chest Discomfort	6 (.28%)
Cholangitis	6 (.28%)
Chronic Hepatitis	6 (.28%)
Drug Hypersensitivity	6 (.28%)
Eosinophilia	6 (.28%)
Erosive Oesophagitis	6 (.28%)
Febrile Neutropenia	6 (.28%)
Gastroduodenitis	6 (.28%)
Giardiasis	6 (.28%)
Haematuria	6 (.28%)
Heart Rate Increased	6 (.28%)
Helicobacter Infection	6 (.28%)
Hyperhidrosis	6 (.28%)
Hypoglycaemic Seizure	6 (.28%)
Leukopenia	6 (.28%)
Myocardial Ischaemia	6 (.28%)
Neoplasm Malignant	6 (.28%)
Neutrophil Count Decreased	6 (.28%)
Oedema Peripheral	6 (.28%)
Pityriasis Rosea	6 (.28%)
Prostate Cancer	6 (.28%)
Rash Generalised	6 (.28%)
Shock	6 (.28%)
Splenectomy	6 (.28%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Nateglinide, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Nateglinide is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Nateglinide

What are the most common Nateglinide adverse events reported to the FDA?

Gastrointestinal Signs	135 (6.26%)
Neurological	83 (3.85%)
Gastrointestinal Inflammatory Condi...	74 (3.43%)
Hepatic And Hepatobiliary	74 (3.43%)
Epidermal And Dermal Conditions	62 (2.88%)
Respiratory	60 (2.78%)
Gastrointestinal Hemorrhages	57 (2.65%)
Gastrointestinal Ulceration And Per...	52 (2.41%)
Glucose Metabolism Disorders	52 (2.41%)
Hematology Investigations	52 (2.41%)
Coronary Artery	49 (2.27%)
	Show More
Cardiac Arrhythmias	45 (2.09%)
Infections - Pathogen Unspecified	42 (1.95%)
Cardiac And Vascular Investigations	39 (1.81%)
Gastrointestinal Motility And Defec...	39 (1.81%)
Exocrine Pancreas Conditions	34 (1.58%)
Renal Disorders	33 (1.53%)
Appetite And General Nutritional	32 (1.48%)
Anemias Nonhemolytic And Marrow Dep...	30 (1.39%)
Cardiac And Vascular Disorders Cong...	30 (1.39%)
Gastrointestinal Therapeutic Proced...	29 (1.35%)
Vascular Hypertensive	29 (1.35%)
Benign Neoplasms Gastrointestinal	27 (1.25%)
Metabolic, Nutritional And Blood Ga...	27 (1.25%)
Gastrointestinal Neoplasms Malignan...	26 (1.21%)
Upper Respiratory Tract Disorders	23 (1.07%)
Vascular	23 (1.07%)
Diverticular	22 (1.02%)
Hepatobiliary	22 (1.02%)
Urinary Tract Signs	21 (.97%)
Enzyme	20 (.93%)
Hematological And Lymphoid Tissue T...	19 (.88%)
Renal And Urinary Tract Investigati...	19 (.88%)
White Blood Cell	19 (.88%)
Electrolyte And Fluid Balance Condi...	18 (.84%)
Lower Respiratory Tract Disorders	18 (.84%)
Musculoskeletal And Connective Tiss...	18 (.84%)
Decreased And Nonspecific Blood Pre...	17 (.79%)
Body Temperature Conditions	16 (.74%)
Seizures	16 (.74%)
Central Nervous System Vascular	15 (.7%)
Physical Examination Topics	15 (.7%)
Bacterial Infectious	14 (.65%)
Injuries	13 (.6%)
Joint	13 (.6%)
Product Quality Issues	13 (.6%)
Bile Duct	12 (.56%)
Protein And Chemistry Analyses	12 (.56%)
Metastases	11 (.51%)
Miscellaneous And Site Unspecified ...	10 (.46%)
Movement Disorders	10 (.46%)
Renal And Urinary Tract Neoplasms M...	10 (.46%)
Therapeutic Procedures And Supporti...	10 (.46%)
Administration Site Reactions	9 (.42%)
Arteriosclerosis, Stenosis, Vascula...	9 (.42%)
Cardiac Disorder Signs	9 (.42%)
Gallbladder	9 (.42%)
Platelet	9 (.42%)
Hepatobiliary Therapeutic Procedure...	8 (.37%)
Lipid Analyses	8 (.37%)
Medication Errors	8 (.37%)
Renal And Urinary Tract Therapeutic...	8 (.37%)
Vascular Hemorrhagic	8 (.37%)
Water, Electrolyte And Mineral	8 (.37%)
Heart Failures	7 (.32%)
Microbiology And Serology	7 (.32%)
Skin Appendage Conditions	7 (.32%)
Therapeutic And Nontherapeutic Effe...	7 (.32%)
Allergic Conditions	6 (.28%)
Cardiac Therapeutic Procedures	6 (.28%)
Oral Soft Tissue Conditions	6 (.28%)
Protozoal Infectious	6 (.28%)
Reproductive Neoplasms Male Maligna...	6 (.28%)
Suicidal And Self-injurious Behavio...	6 (.28%)
Thyroid Gland	6 (.28%)
Tissue	6 (.28%)
Deliria	5 (.23%)
Gastrointestinal Tract Disorders Co...	5 (.23%)
Lifestyle Issues	5 (.23%)
Pleural	5 (.23%)
Abdominal Hernias And Other Abdomin...	4 (.19%)
Fatal Outcomes	4 (.19%)
Gastrointestinal Vascular Condition...	4 (.19%)
Inner Ear And Viiith Cranial Nerve	4 (.19%)
Lymphomas Non-hodgkins B-cell	4 (.19%)
Myocardial	4 (.19%)
Sleep Disorders	4 (.19%)
Urolithiases	4 (.19%)
Vascular Therapeutic Procedures	4 (.19%)
Vision	4 (.19%)
Acid-base	3 (.14%)
Bone And Joint Injuries	3 (.14%)
Chemical Injury And Poisoning	3 (.14%)
Coagulopathies And Bleeding Diathes...	3 (.14%)
Immunology And Allergy	3 (.14%)
Investigations, Imaging And Histopa...	3 (.14%)
Peritoneal And Retroperitoneal Cond...	3 (.14%)
Reproductive Tract	3 (.14%)
Anxiety Disorders	2 (.09%)
Bone And Joint Therapeutic Procedur...	2 (.09%)
Bronchial Disorders	2 (.09%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Nateglinide, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Nateglinide is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.